Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any Age.

Abstract

CLINICAL QUESTION:

Are pathogen-reduced platelets as effective as standard platelets for the prevention of bleeding in people of any age requiring platelet transfusions?

BOTTOM LINE:

In people with cancer who have a low platelet count due to their disease or its treatment, pathogen-reduced platelet transfusions increase risk of platelet refractoriness and platelet transfusion requirement (high-quality evidence) but probably do not effect all-cause mortality, risk of clinically significant or severe bleeding, or risk of a serious adverse event (moderate-quality evidence). There was insufficient evidence for people with other diagnoses.

• Authors: Lise J Estcourt, Reem Malouf, Michael F Murphy
• Journal: JAMA oncology (JAMA Oncol) Vol. 4 Issue 4 Pg. 571-572 (Apr 01 2018) ISSN: 2374-2445 [Electronic] United States
• PMID: 29372241 (Publication Type: Journal Article, Meta-Analysis, Review)

Topics

• Adolescent
• Adult
• Age Factors
• Aged
• Aged, 80 and over
• Blood Safety (methods, standards)
• Child
• Child, Preschool
• Disease Transmission, Infectious (prevention & control)
• Disinfection (methods)
• Hemorrhage (epidemiology, prevention & control)
• Humans
• Middle Aged
• Neoplasms (complications, epidemiology, therapy)
• Platelet Transfusion (methods, statistics & numerical data)
• Thrombocytopenia (complications, epidemiology, therapy)
• Young Adult